Related references
Note: Only part of the references are listed.Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study
Amer Budayr et al.
BMC ENDOCRINE DISORDERS (2020)
Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles
Yasmin A. Bassiouny et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2018)
Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome
Emaduldin Seyam et al.
GYNECOLOGICAL ENDOCRINOLOGY (2018)
Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: A randomized clinical trial
Mohamed Anwar Elnory et al.
MIDDLE EAST FERTILITY SOCIETY JOURNAL (2018)
Clomiphene citrate plus cabergoline versus clomiphene citrate for induction of ovulation in infertile euprolactinemic patients with polycystic ovary syndrome: A randomized clinical trial
Kamal M. Zahran et al.
MIDDLE EAST FERTILITY SOCIETY JOURNAL (2018)
Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome
S. Jellad et al.
JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION (2017)
Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome
Ahmed Samy Saad et al.
MIDDLE EAST FERTILITY SOCIETY JOURNAL (2017)
GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial
Usama M. Fouda et al.
JOURNAL OF OVARIAN RESEARCH (2016)
Pharmacologic Interventions in Preventing Ovarian Hyperstimulation Syndrome: A Systematic Review and Network Meta-Analysis
Jun-Liang Guo et al.
SCIENTIFIC REPORTS (2016)
Volume expanders for the prevention of ovarian hyperstimulation syndrome
Mohamed A. Youssef et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2016)
Reducing the Risk of OHSS by GnRH Agonist Triggering
Robert F. Casper
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes
M. L. Walls et al.
HUMAN REPRODUCTION (2015)
Luteal phase support for assisted reproduction cycles
Michelle van der Linden et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)
Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials
Valeria M. S. Leitao et al.
FERTILITY AND STERILITY (2014)
Dopamine agonists in prevention of ovarian hyperstimulation syndrome
Miro Kasum et al.
GYNECOLOGICAL ENDOCRINOLOGY (2014)
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome
Leopoldo O. Tso et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch
Roberto Matorras et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2013)
The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study
Ana Lucia Beltrame et al.
GYNECOLOGICAL ENDOCRINOLOGY (2013)
Cabergoline as treatment of ovarian hyperstimulation syndrome: a review
Theodoros Kalampokas et al.
GYNECOLOGICAL ENDOCRINOLOGY (2013)
Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial
Kok-Min Seow et al.
REPRODUCTIVE BIOMEDICINE ONLINE (2013)
Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis
Miriam Baumgarten et al.
HUMAN FERTILITY (2013)
The treatment of infertility in polycystic ovary syndrome: a brief update
Michael F. Costello et al.
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY (2012)
Risk of Cardiac Valve Regurgitation with Dopamine Agonist use in Parkinson's Disease and Hyperprolactinaemia A Multi-Country, Nested Case-Control Study
Gianluca Trifiro et al.
DRUG SAFETY (2012)
Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study
Amany Shaltout et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2012)
Etiology of OHSS and use of dopamine agonists
Sergio Reis Soares
FERTILITY AND STERILITY (2012)
Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial
Ensieh Shahrokh Tehraninejad et al.
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS (2012)
IVF versus ICSI for the fertilization of in-vitro matured human oocytes
M. Walls et al.
REPRODUCTIVE BIOMEDICINE ONLINE (2012)
Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome
Dietmar Spitzer et al.
FERTILITY AND STERILITY (2011)
CAN DOPAMINE AGONIST CABERGOLINE REDUCE OVARIAN HYPERSTIMULATION SYNDROME IN ART TREATMENT CYCLES? A PROSPECTIVE RANDOMIZED STUDY
H. Amir et al.
FERTILITY AND STERILITY (2011)
THE EFFECTS OF CABERGOLINE ON OVARIAN HYPERSTIMULATION SYNDROME (OHSS) AND PREGNANCY OUTCOMES ON IN VITRO FERTILIZATION (IVF) PATIENTS
M. Gualtieri et al.
FERTILITY AND STERILITY (2011)
Cabergoline vs intravenous albumin or combination of both for prevention of the early onset ovarian hyperstimulation syndrome
Badeea Soliman
MIDDLE EAST FERTILITY SOCIETY JOURNAL (2011)
Gonadotrophin-releasing hormone antagonists for assisted reproductive technology
Hesham G. Al-Inany et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2011)
Cabergoline and Ganirelix Therapy for Early Moderate to Severe Ovarian Hyperstimulation Syndrome (OHSS) Results in Faster Recovery than in Early Untreated OHSS.
Z. Khan et al.
FERTILITY AND STERILITY (2010)
THE EFFECT OF CABERGOLINE ON FOLICULAR MICROENVIROMENT PROFILE IN PATIENTS WITH HIGH RISK OF OHSS.
E. S. Guvendag Guven et al.
FERTILITY AND STERILITY (2010)
Preventing ovarian hyperstimulation syndrome: guidance for the clinician
Peter Humaidan et al.
FERTILITY AND STERILITY (2010)
The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial†
Cristiano Busso et al.
HUMAN REPRODUCTION (2010)
Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis
Mohamed A. F. M. Youssef et al.
HUMAN REPRODUCTION UPDATE (2010)
100 CABERGOLINE VERSUS HUMAN ALBUMIN IN PROPHYLAXY OF OVARIAN HYPERSTIMULATION SYNDROME
Sh. Ahmadi et al.
REPRODUCTIVE BIOMEDICINE ONLINE (2010)
Ovarian hyperstimulation syndrome and complications of ART
Veerle Vloeberghs et al.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2009)
High dose cabergoline in management of ovarian hyperstimulation syndrome
Baris Ata et al.
FERTILITY AND STERILITY (2009)
Cabergoline and ganirelix treatment of ovarian hyperstimulation syndrome (OHSS) results in rapid clinical improvement
N.L. Rollene et al.
FERTILITY AND STERILITY (2009)
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series
Nanette L. Rollene et al.
FERTILITY AND STERILITY (2009)
Prevention of OHSS - dopamine agonists
Cristiano E. Busso et al.
REPRODUCTIVE BIOMEDICINE ONLINE (2009)
Prevention of OHSS
Mohamed Aboulghar
REPRODUCTIVE BIOMEDICINE ONLINE (2009)
Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome
Sergio Reis Soares et al.
HUMAN REPRODUCTION UPDATE (2008)
Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma
Marleen Kars et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study
Carlos Carizza et al.
REPRODUCTIVE BIOMEDICINE ONLINE (2008)
Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction
Claudio Alvarez et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
IVF, IVM natural cycle IVF, minimal stimulation IVF - time for a rethink
R. G. Edwards
REPRODUCTIVE BIOMEDICINE ONLINE (2007)
Dopamine agonists and the risk of cardiac-valve regurgitation
Rene Schade et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Valvular heart disease and the use of dopamine agonists for Parkinson's disease
Renzo Zanettini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Embryo freezing for preventing ovarian hyperstimulation syndrome (Withdrawn Paper. 2007, art. no. CD002806)
A. D' Angelo et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2007)
Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model
Raul Gomez et al.
ENDOCRINOLOGY (2006)
The vascular endothelial growth factor (VEGF) VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent
SA Pauli et al.
ENDOCRINOLOGY (2005)
Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome?
M Manno et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2005)
Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures
MA Aboulghar et al.
HUMAN REPRODUCTION UPDATE (2003)
Inhibition of vascular endothelial growth factor/vascular permeability factor action blocks estrogen-induced uterine edema and implantation in rodents
LC Rockwell et al.
BIOLOGY OF REPRODUCTION (2002)
Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade
R Gómez et al.
ENDOCRINOLOGY (2002)
A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients
A Delvigne et al.
HUMAN REPRODUCTION UPDATE (2002)
Share Paper
